Clinical trials: Prostatic Disease
Prostate Cancer
Study Evaluating the Correlation Between C-11 Acetate Uptake and Retention as Measured by PET and FAS in Prostate Cancer
The purpose of this study is to understand if a new type of radiology test called positron emission tomography (PET) with carbon 11 acetate will help us to understand which cancers produce more of a protein called fatty acid…
- Trial name
- NCT00139191
- Testing
- C-11 acetate PET scan
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Neoplasm
18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer
This pilot clinical trial studies how well fluorine F 18 d-FMAU (18F-FMAU) positron emission tomography (PET)/computed tomography (CT) works in diagnosing and characterizing prostate cancer.
- Trial name
- NCT02809690
- Testing
- CAT, 18F-FMAU, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Southern California
Prostate Cancer Metastatic
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
The purpose of this study is to determine whether PROSTVAC alone or in combination with GM-CSF is effective in prolonging overall survival in men with few or no symptoms from metastatic, castrate-resistant prostate cancer.
- Trial name
- Prospect (NCT01322490)
- Testing
- PROSTVAC-V, PROSTVAC-F, GM-CSF
- Where
- 220 sites in United States, Australia and 14 more
- Volunteers
- 1,297 people
- Sponsor
- Bavarian Nordic
Malignant Neoplasm of Prostate
68Ga-AAZTA-093 PET/CT: First-in-human Study
68Ga-AAZTA-093 is a novel radiotracer targeting prostate-specific membrane antigen (PSMA). In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-AAZTA-093 PET/CT in patients with…
- Trial name
- NCT06437496
- Testing
- 68Ga-AAZTA-093, 68Ga-PSMA-11//68Ga-PSMA-617
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
MGC018 With or Without MGA012 in Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of vobramitamab duocarmazine (MGC018) in patients with advanced solid tumors.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult
- Trial name
- NCT03729596
- Testing
- vobramitamab duocarmazine
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 143 people
- Sponsor
- MacroGenics
Prostate Cancer
Photon-Counting Computed Tomography-Based Urethral Visualization Without Catheterization for Radiotherapy Planning: A Prospective Pilot Study Under ANTHEM
In prostate cancer radiotherapy, it is important to accurately identify and protect healthy organs near the prostate. One of these structures is the urethra, the tube that carries urine from the bladder out of the body.
- Trial name
- PURE-CT/ANTHEM (NCT07730203)
- Testing
- image acquisition
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Istituto Clinico Humanitas
Low Anterior Resection Syndrome, Malignant Anal Neoplasm
Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study
This phase II trial studies how well sacral nerve stimulation works in treating low anterior resection syndrome or fecal incontinence (the body's passage of stool without control) in patients with rectal cancer that has spread to…
- Conditions
- Low Anterior Resection Syndrome, Malignant Anal Neoplasm, Malignant Bladder Neoplasm, Malignant Cervical Neoplasm
- Trial name
- NCT04066894
- Testing
- Explantation, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer, Prostatic Cancer
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
The purpose of this study is to investigate the effects of CyberKnife radiosurgery in patients with early stage organ-confined prostate cancer and to evaluate the effects of this treatment on the quality of life over time.
- Conditions
- Prostate Cancer, Prostatic Cancer, Prostatic Neoplasms, Prostate Neoplasms
- Trial name
- NCT00643617
- Testing
- CyberKnife Stereotactic Radiosurgery - Low Risk, CyberKnife Stereotactic Radiosurgery - Intermediate Risk
- Where
- 18 sites in United States
- Volunteers
- 307 people
- Sponsor
- Accuray Incorporated
Urinary Incontinence
Whole Body Vibration and Pelvic Floor Exercises on Urinary Incontinence
Stress urinary incontinence is common in men following prostate cancer surgery. Rehabilitative interventions incorporate pelvic floor muscle training, biofeedback, electrical stimulation, lifestyle changes, or a combination of…
- Trial name
- [PTREC] (NCT03325660)
- Testing
- whole body vibration
- Volunteers
- 61 people
- Sponsor
- Ahlia University
Prostate Cancer
Evaluation of Lithium and It's Effect on Clinically Localized Prostate Cancer
Laboratory testing has suggested that lithium may decrease the incidence of certain types of cancer, including prostate cancer. Additional research has suggested that lithium decreases prostate cancer tumor size over time.
- Trial name
- NCT02198859
- Testing
- Lithium Carbonate
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Kansas Medical Center
Breast Cancer, Prostate Cancer
Lighting Intervention for Cancer-related Fatigue
Fatigue is a major problem for cancer patients, and one that can persist long after treatment ends. Recent work has demonstrated that light therapy may mitigate or reduce fatigue levels in both cancer patients and cancer…
- Conditions
- Breast Cancer, Prostate Cancer, Hematologic Malignancy, Survivorship
- Trial name
- NCT04827446
- Testing
- Wearable Sensor, Blue-blocking glasses, Clear glasses
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostate Biopsy, Antibiotic
Transperineal MRI-TRUS Fusion Guided Prostate Biopsy With vs Without Antibiotic Prophylaxis
Prostate biopsy is indicated in patients with suspected prostate cancer and has been traditionally performed through the rectum using antibiotic prophylaxis.
- Trial name
- NORAPP (NCT04146142)
- Testing
- Transperineal prostate biopsy with or without antibiotic prophylaxis
- Where
- 2 sites in Germany, Norway
- Volunteers
- 550 people
- Sponsor
- Oslo University Hospital
Prostate Cancer
Stereotactic Body Radiotherapy (SBRT) With Concurrent Boost for Low- and Intermediate-Risk Prostate Cancer
The purpose of this study is to determine whether stereotactic body radiation therapy (SBRT) with simultaneous boost (higher radiation dose) to areas within the prostate with more prominent cancerous growth (intraprostatic…
- Trial name
- Prostate SBRT (NCT01409473)
- Testing
- Prostate SBRT with concurrent boost to intraprostatic lesion(s)
- Where
- 2 sites in United States
- Sponsor
- Rocky Mountain Cancer Centers
Prostate Cancer
ClariCore™ Biopsy System in Patients Undergoing Radical Retropubic Prostatectomy
The purpose of the study is to collect information on prostate tissue biopsies collected with the ClariCore System during a radical prostatectomy procedure.
- Trial name
- NCT02773940
- Testing
- ClariCore System
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Precision Biopsy, Inc.
Benign Prostatic Hyperplasia
Modified Water Vapor Thermal Therapy in Management of Patients With Large-volume Benign Prostatic Hyperplasia
Water vapor thermal therapy (Rezum) is a minimally invasive treatment for benign prostatic hyperplasia (BPH) that uses injections of sterile water vapor directly into the prostate for tissue ablation.
- Trial name
- NCT06596590
- Testing
- Rezum
- Where
- China
- Volunteers
- 76 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer, Localized Prostate Carcinoma
Erectile Function PRESERVation in Definitive Radiotherapy for Prostate Cancer by MRI-Enhanced Adaptive Sparing of the Neurovascular Bundle
Radiotherapy is a standard and highly effective treatment for prostate cancer that is confined to the prostate gland. One modern approach, called stereotactic body radiotherapy (SBRT), delivers treatment in just five sessions and…
- Conditions
- Prostate Cancer, Localized Prostate Carcinoma, Low-Risk Prostate Cancer, Intermediate-risk Prostate Cancer
- Trial name
- EF-PRESERVE (NCT07916779)
- Testing
- Daily Adaptive MR-Enhanced SBRT with Neurovascular Bundle Sparing
- Where
- Switzerland
- Volunteers
- 48 people
- Sponsor
- University of Zurich
Castration-resistant Prostate Cancer, Metastatic Cancer
Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.
Open-label phase II multi-centre single arm study of Denosumab in combination with enzalutamide in progressive metastatic castrate-resistant prostate cancer.
- Conditions
- Castration-resistant Prostate Cancer, Metastatic Cancer, Bone Metastases
- Trial name
- DICE (NCT03869762)
- Testing
- Xgeva, Xtandi
- Where
- 7 sites in Ireland
- Volunteers
- 7 people
- Sponsor
- Cancer Trials Ireland
Prostatic Neoplasms
Single Fraction HDR Brachytherapy Plus Hypofractionated EBRT for Low-risk Prostate Cancer: Phase II Trial
The hypofractionated external radiation (EBRT) is a technique that radiation dose delivery using higher daily fractions than those used routinely.
- Trial name
- AC-P01 (NCT02283346)
- Testing
- HDR brachytherapy + hypofractionated EBRT
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- AC Camargo Cancer Center
Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer
This clinical trial tests the effect of focal radiation therapy, high dose rate-brachytherapy (HDR-BT), in treating patients with prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8
- Trial name
- NCT07468903
- Testing
- Biopsy Procedure, Biospecimen Collection, High-Dose Rate Brachytherapy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Neoplasm, Prostate
Androgen Deprivation Therapy, External Beam Radiotherapy and Stereotactic Radiosurgery Boost for Prostate Cancer
For the treatment for intermediate- and high-risk prostate cancer, Cyberknife boost will be used after 4 weeks of intensity modulated radiotherapy to pelvis. The boost doses are 18 Gy and 21 Gy in 3 fractions, respectively.
- Trial name
- ADEBAR (NCT03322020)
- Testing
- Cyberknife boost 18 Gy, Cyberknife boost 21 Gy
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Asan Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.